• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600161.SS
Share

Beijing Tiantan Biological Products Co., Ltd. Stocks

CN¥ 13.15Last Updated 28.05.2026

Issuer Rating

5/7
Performance

Average

Risk

Low

Recommendation

Hold

Market Cap

CN¥ 3.87B

CN¥ 13.15
Key Takeaways

Risk factor

Low price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and consulting of blood products in China. Its products include blood intravenous injection immunoglobulin; blood human albumin; blood system intravenous injection; hepatitis B, freeze-dried hepatitis B, and tetanus human immunoglobulin; human immunoglobulin; and other blood products. The company was incorporated in 1998 and is headquartered in Beijing, China. Beijing Tiantan Biological Products Co., Ltd. operates as a subsidiary of China National Biotec Group Company Limited.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

29.05.2026 01:39

U.S. stock market hits four records: investors await U.S.-Iran agreement

29.05.2026 00:43

Anthropic has surpassed OpenAI to become the most expensive AI startup. The valuation is close to $1 trillion

29.05.2026 00:08

Anthropic has introduced a new AI model. It can doubt the accuracy of its answers

28.05.2026 23:49

Stocks rebound: investors encouraged by the announcement of the US-Iran deal

28.05.2026 23:08

The world's richest families have sold off $1 billion worth of stocks while the market is at peak value

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026